At a congressional hearing on Tuesday, executives from the three largest pharmacy benefit manager companies insisted that their role as pharma middlemen help promote competition in the industry and effectively lower drug prices for U.S. consumers. Tuesday’s hearing was held by the House Committee on Oversight and Accountability amid the growing bipartisan scrutiny on rising …

Read More